Literature DB >> 25520399

Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1.

Evelyn Hartung1, Martina Becker1, Annabell Bachem1, Nele Reeg1, Anika Jäkel1, Andreas Hutloff1, Harald Weber1, Christoph Weise2, Claudia Giesecke3, Volker Henn1, Stephanie Gurka1, Konstantinos Anastassiadis4, Hans W Mages1, Richard A Kroczek5.   

Abstract

Current subunit vaccines are incapable of inducing Ag-specific CD8(+) T cell cytotoxicity needed for the defense of certain infections and for therapy of neoplastic diseases. In experimental vaccines, cytotoxic responses can be elicited by targeting of Ag into cross-presenting dendritic cells (DC), but almost all available systems use target molecules also expressed on other cells and thus lack the desired specificity. In the present work, we induced CD8(+) T cell cytotoxicity by targeting of Ag to XCR1, a chemokine receptor exclusively expressed on murine and human cross-presenting DC. Targeting of Ag with a mAb or the chemokine ligand XCL1 was highly specific, as determined with XCR1-deficient mice. When applied together with an adjuvant, both vector systems induced a potent cytotoxic response preventing the outgrowth of an inoculated aggressive tumor. By generating a transgenic mouse only expressing the human XCR1 on its cross-presenting DC, we could demonstrate that targeting of Ag using human XCL1 as vector is fully effective in vivo. The specificity and efficiency of XCR1-mediated Ag targeting to cross-presenting DC, combined with its lack of adverse effects, make this system a prime candidate for the development of therapeutic cytotoxic vaccines in humans.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25520399     DOI: 10.4049/jimmunol.1401903

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Towards superior dendritic-cell vaccines for cancer therapy.

Authors:  Mansi Saxena; Sreekumar Balan; Vladimir Roudko; Nina Bhardwaj
Journal:  Nat Biomed Eng       Date:  2018-06-11       Impact factor: 25.671

Review 2.  The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules.

Authors:  Freidrich M Cruz; Jeff D Colbert; Elena Merino; Barry A Kriegsman; Kenneth L Rock
Journal:  Annu Rev Immunol       Date:  2017-01-11       Impact factor: 28.527

Review 3.  Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.

Authors:  Sreekumar Balan; John Finnigan; Nina Bhardwaj
Journal:  Cancer J       Date:  2017 Mar/Apr       Impact factor: 3.360

Review 4.  Dendritic cell-based immunotherapy.

Authors:  Rachel L Sabado; Sreekumar Balan; Nina Bhardwaj
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

5.  Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition.

Authors:  Kirsteen M Tullett; Ingrid M Leal Rojas; Yoshihito Minoda; Peck S Tan; Jian-Guo Zhang; Corey Smith; Rajiv Khanna; Ken Shortman; Irina Caminschi; Mireille H Lahoud; Kristen J Radford
Journal:  JCI Insight       Date:  2016-05-19

6.  Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.

Authors:  Dallas B Flies; Tomoe Higuchi; Jaryse C Harris; Vibha Jha; Phyllis A Gimotty; Sarah F Adams
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

Review 7.  Genetic models of human and mouse dendritic cell development and function.

Authors:  David A Anderson; Charles-Antoine Dutertre; Florent Ginhoux; Kenneth M Murphy
Journal:  Nat Rev Immunol       Date:  2020-09-09       Impact factor: 53.106

Review 8.  Insights Into Human Intrahepatic NK Cell Function From Single Cell RNA Sequencing Datasets.

Authors:  Gráinne Jameson; Mark W Robinson
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

Review 9.  Transcriptional Control of Dendritic Cell Development.

Authors:  Theresa L Murphy; Gary E Grajales-Reyes; Xiaodi Wu; Roxane Tussiwand; Carlos G Briseño; Arifumi Iwata; Nicole M Kretzer; Vivek Durai; Kenneth M Murphy
Journal:  Annu Rev Immunol       Date:  2015-12-23       Impact factor: 28.527

Review 10.  Recent Progress in Dendritic Cell-Based Cancer Immunotherapy.

Authors:  Kazuhiko Matsuo; Osamu Yoshie; Kosuke Kitahata; Momo Kamei; Yuta Hara; Takashi Nakayama
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.